Cover Image
市場調查報告書

CC趨化素受體1 (HM145,LD78受體,巨噬細胞發炎性蛋白質1α受體,CD191,CCR1) :開發平台分析

C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1 Alpha Receptor or RANTES R or CD191 or CCR1) - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 361646
出版日期 內容資訊 英文 35 Pages
訂單完成後即時交付
價格
Back to Top
CC趨化素受體1 (HM145,LD78受體,巨噬細胞發炎性蛋白質1α受體,CD191,CCR1) :開發平台分析 C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1 Alpha Receptor or RANTES R or CD191 or CCR1) - Pipeline Review, H2 2017
出版日期: 2017年10月31日 內容資訊: 英文 35 Pages
簡介

本報告提供CC趨化素受體1 (HM145,LD78受體,巨噬細胞發炎性蛋白質1α受體,CD191,CCR1)的開發情形調查分析,開發中產品的概要,臨床實驗的各階段的產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等系統性資訊。

目錄

簡介

概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:各適應症

開發中產品的概要

  • 後期階段的產品
  • 初期階段的產品

開發中的產品:各企業

治療藥的評估

  • 單劑/聯合治療
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

開發治療藥的企業

  • Bristol-Myers Squibb Company
  • ChemoCentryx, Inc.
  • Ligand Pharmaceuticals, Inc.

藥物簡介

暫停的計劃

開發中止的產品

最新消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC1086TDB

Summary:

C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1 Alpha Receptor or RANTES R or CD191 or CCR1) pipeline Target constitutes close to 7 molecules. Out of which approximately 7 molecules are developed by Companies. The latest report C-C Chemokine Receptor Type 1 - Pipeline Review, H2 2017, outlays comprehensive information on the C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1 Alpha Receptor or RANTES R or CD191 or CCR1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1 Alpha Receptor or RANTES R or CD191 or CCR1) - C-C chemokine receptor type 1 is a protein encoded by the CCR1 gene. CCR1 binds to multiple chemokines (including CCL4, CCL5, CCL6, CCL14, CCL15, CCL16 and CCL23). This receptor is found on peripheral blood lymphocytes and monocytes. This chemokine receptor is restricted to memory T-cells within the lymphocyte pool. This receptor is also designated cluster of differentiation marker CD191. The molecules developed by companies in Phase II and Preclinical stages are 1 and 6 respectively. Report covers products from therapy areas Immunology, Oncology and Infectious Disease which include indications Rheumatoid Arthritis, Autoimmune Disorders, Blood Cancer, Bone Metastasis, Breast Cancer, Lupus Nephritis and Systemic Candidiasis.

Furthermore, this report also reviews key players involved in C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1 Alpha Receptor or RANTES R or CD191 or CCR1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1 Alpha Receptor or RANTES R or CD191 or CCR1)
  • The report reviews C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1 Alpha Receptor or RANTES R or CD191 or CCR1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1 Alpha Receptor or RANTES R or CD191 or CCR1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1 Alpha Receptor or RANTES R or CD191 or CCR1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1 Alpha Receptor or RANTES R or CD191 or CCR1) targeted therapeutics

Reasons to buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1 Alpha Receptor or RANTES R or CD191 or CCR1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1 Alpha Receptor or RANTES R or CD191 or CCR1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1 Alpha Receptor or RANTES R or CD191 or CCR1) - Overview
    • C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1 Alpha Receptor or RANTES R or CD191 or CCR1) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
  • C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1 Alpha Receptor or RANTES R or CD191 or CCR1) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1 Alpha Receptor or RANTES R or CD191 or CCR1) - Companies Involved in Therapeutics Development
    • Bristol-Myers Squibb Co
    • ChemoCentryx Inc
    • Ligand Pharmaceuticals Inc
    • Novartis AG
  • C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1 Alpha Receptor or RANTES R or CD191 or CCR1) - Drug Profiles
    • BL-5923 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BMS-457 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CCX-354 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CCX-9588 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Antagonize CCR1 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Antagonize CCR1 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Antagonize CCR1,4,5,6 and CXCR2,7 for Oncology and Autoimmune Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1 Alpha Receptor or RANTES R or CD191 or CCR1) - Dormant Products
  • C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1 Alpha Receptor or RANTES R or CD191 or CCR1) - Discontinued Products
  • C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1 Alpha Receptor or RANTES R or CD191 or CCR1) - Product Development Milestones
    • Featured News & Press Releases
      • Apr 18, 2016: ChemoCentryx Announces Immuno-Oncology Data Presentation at the American Association for Cancer Research (AACR) Annual Meeting
      • Nov 04, 2015: ChemoCentryx presents CCX-9588 preclinical results at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Meeting
      • Jun 08, 2012: ChemoCentryx Announces Peer-Reviewed Publication Of Positive Phase II Clinical Data With CCX354 In Patients With Rheumatoid Arthritis
      • Nov 08, 2011: ChemoCentryx Reports Clinical Efficacy For CCX354 In Phase II Study In Patients With Rheumatoid Arthritis
      • Nov 09, 2010: ChemoCentryx Reports Favorable Phase I Results For CCX354 In Rheumatoid Arthritis At Annual American College Of Rheumatology Meeting
      • Jun 17, 2010: ChemoCentryx Reports Positive Phase I Study Results For CCX354
      • Dec 16, 2009: ChemoCentryx Initiates Phase 2 Clinical Trial Of CCX354 For The Treatment Of Rheumatoid Arthritis
      • May 13, 2008: ChemoCentryx Initiates Clinical Trial Of CCX354 For The Treatment Of Inflammatory Disease
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H2 2017
  • Number of Products under Development by Therapy Areas, H2 2017
  • Number of Products under Development by Indication, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Pipeline by Bristol-Myers Squibb Co, H2 2017
  • Pipeline by ChemoCentryx Inc, H2 2017
  • Pipeline by Ligand Pharmaceuticals Inc, H2 2017
  • Pipeline by Novartis AG, H2 2017
  • Dormant Projects, H2 2017
  • Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development by Stage of Development, H2 2017
  • Number of Products under Development by Therapy Areas, H2 2017
  • Number of Products under Development by Indications, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
Back to Top